In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Through a trust, Dudum sold about $33.4 million worth of his company's stock on Thursday, according to a filing with the Securities and Exchange Commission put out after Monday's closing bell. The CEO ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over Wegovy drug sales, and Apollo Hospitals' increased AI investments. The CDC ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.